(DHR)

DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt.

Besides Wall Street's top -and-bottom-line estimates for Danaher (DHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the qua...

Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Citi added Danaher to the firm's Focus List while keeping a Buy rating on the shares with a $265 price target. The firm sees an attractive opportunity to step into the name, saying the bioprocessing r...

DHR is poised to gain from strength in the clinical diagnostics business, the Abcam buyout and shareholder-friendly policies. Softness in Life Sciences and Biotechnology units remains a concern.

I linked investing to baseball, showing how consistency, like the A's Moneyball approach, wins long term. Steady dividend growers and low-volatility stocks outperform, especially in rocky markets. Top...

Danaher Corporation incorporates science and technology and has a market cap of $150B. The company has mixed financials, with its gross profit margin being its strongest and most consistent. DHR doesn...

Danaher is well-positioned for revenue growth, driven by strong Biotechnology orders, Chinese stimulus in Life Sciences, and innovative products in Diagnostics despite near-term headwinds. Margins fac...

Highlighting eight companies with upcoming dividend increases, four exceeding 10%, and an average increase of 11.4%, median at 9%. My investment strategy focuses on buying, holding, and expanding stak...

Danaher Corporation is trading near its 5-year low, presenting a potential buying opportunity for growth investors despite near-term headwinds. DHR's strong fundamentals include leadership in biotechn...